研究团队   Member
联系我们   Contact
你的位置:首页 > 研究团队 > 老师组

韩博教授

2015-2-3 23:21:52

暂无图片。

详细介绍



    韩博,男,45岁。山东大学教授,博士生导师,山东大学齐鲁医学院基础医学院病理学系副主任兼齐鲁医院病理科副主任。2000年获山东医科大学病理学硕士学位。2002-2006年在日本和歌山县立医科大学攻读病理学博士学位。2006年毕业后至美国密歇根大学医学院病理系做博士后研究。2010年3月回国后,受聘为山东大学教授并工作至今。

    从事病理学专业19年,热爱临床病理外检工作,每年独立签发约4500份病理诊断报告,无诊断差错。擅长泌尿及男性生殖系统疾病的病理诊断,在前列腺癌的诊断及鉴别诊断方面有较深入的研究。主持科室的病理质量控制工作及分子病理平台建设和临床检测工作的开展。作为山东病理学会分子病理学组及分子病理协作组组长,在推动山东省医院病理科分子病理检测工作的协助方面发挥了积极的作用。作为教学分管主任,参与并组织了科室的各项教学工作。作为课程负责人,主持面向研究生的分子病理学全英文课程。目前指导博士生15人(在职博士生10人),硕士生6人。博士生已毕业5人,硕士生已毕业6人。分别作为主编及编者,参与编写了两部病理学理论和实验学教材。

    自2002年起一直从事恶性肿瘤的发生和演进的机理研究。主持国家自然科学基金面上项目5项(批准号分别为81972416,81072110、81472417、81171951和81672554),已结题3项;主持国家自然科学基金海外及港澳学者合作研究基金1项(批准号为81528015);主持教育部留学回国人员科研启动基金1项;参与国家自然科学基金重点项目1项(批准号为81330050,第二位)。主持/参与省市及山东大学科学基金项目多项。已在SCI医学杂志上发表论文近70篇,其中包括 Science、 Nature、Cell、Nature Medicine等杂志的署名作者文章7篇,合计影响因子大于300;第一作者及通讯作者文章30余篇,合计影响因子大于100;单篇论文影响因子最高9.329。近五年来,在上述领域中的论文已被他引382次,单篇引用最高次数为191次。其中第一作者论文被他引21次,单篇引用最高次数为21次。曾多次参加日本和美国的国际学术会议并宣读论文。2003年和2004年分别获日本大桑文化基金优秀留学生奖励金和国际组织化学和细胞化学联盟青年组织化学家奖。2008年获密西根大学癌症研究年会学术论文评选第二名。2009年获在美中国人病理学会最佳年度论文摘要奖。2014年获得山东大学齐鲁医院杰出青年荣誉称号。2015年获山东省医学科技创新成果奖二等奖1项。2016年获山东省高等学校科学技术成果奖二等奖1项。2016年获中国杰出青年病理医师荣誉称号。2018年获山东省优秀医师称号。目前担任全国基础医学形态学实验室主任联席会副会长,吴阶平医学基金会病理学部常务委员,中华医学会病理学分会泌尿及男性生殖组委员,中国病理学工作者委员会常务委员,山东省医师协会病理科医师分会副主任委员,山东省病理学会青年委员会常务副主任委员,山东大学学报(医学版)常务编委,来华留学生(医学) 教学专业委员会委员,医学实验室国家认可委员会评审员,山东省医师协会组织样本库及转化医学医师分会委员等职。


主持的科研基金课题

1. “SOX4协同PLXNA1促进神经内分泌前列腺癌转化的作用和机制研究”。国家基金面上项目,2019年。批准号:81972416。第一位,55万元。

2. 国家重点研发计划 "区域医疗中心指导下基于国产创新诊疗装备提升基层服务能力分级诊疗模式和临床路径的建立与示范 (编号:2018YFC0114700)" 子课题项目。第一位,2018年,100万元。

3. 2018年山东大学基本科研业务费资助项目-自然科学专项(交叉学科培育项目)项目名称:惰性和侵袭性前列腺癌的精准诊疗及预后评估的跨组学分析及肿瘤驱动基因的识别。项目编号:2018JC016,  25万元。

4. “CUL4B在前列腺癌恶性进展中的作用及其调控机制的研究”。国家基金面上项目,2016年。批准号:81672554。第一位,62万元。

5. “TXNDC5在去势抵抗性前列腺癌中的特征分析及临床转化研究”。山东省科技厅攻关计划,2016年。批准号:2016GSF201170。第一位,10万元。

6. “lncRNA在去势抵抗性前列腺癌中的作用及其机制研究”。 国家自然科学基金海外及港澳学者合作研究基金,2015年。批准号:81528015。共同申请人,20万元。

7. “SOX4在去势抵抗性前列腺癌中的作用及其机制研究”。国家自然科学基金面上项目, 2014年。批准号: 81472417。第一位,75万元。

8. “泛素连接酶复合物骨架蛋白CUL4B在调控肿瘤干细胞形成和自我更新中的作用及其机制研究” 国家自然科学基金重点项目,2014年。批准号:81330050, 第二位,290万元。

9. “ETS 基因融合在我国前列腺癌中的特征分析与临床转化的研究”。教育部留学回国人员科研启动基金, 2012年(第44批)。第一位,3万元。(已结题)

10. “乳腺癌非随机性融合基因的鉴定和特性分析的研究”。国家自然科学基金面上项目,2011年。批准号: 81171951,第一位,60万元。(已结题)

11. “前列腺癌ETS基因重排的高通量筛选及临床转化的研究”。山东大学自主创新基金项目。批准号:2010TB012,第一位,15万元。 (已结题)

12. “ETS 基因融合在我国前列腺癌中的特征分析与临床转化的研究”。国家自然科学基金面上项目, 2010年。批准号: 81072110。第一位,36万元。 (已结题)


奖 励

1. 山东省科技进步二等奖  2019年

2. 山东省优秀医师  2018年

3. 中国杰出青年病理医师  2016年

4. 山东省高等学校科学技术成果奖二等奖  2016年

5. 山东省医学科技创新成果奖二等奖  2015年

6. 山东大学齐鲁医院杰出青年  2014年

7. 最佳年度论文摘要奖 在美中国人病理学会 2009年

8. 大会学术论文评选第二名 密西根大学癌症研究年会 2008年

9. 大桑文化基金优秀留学生奖励金 日本大桑财团 2003年

10. 青年组织化学家奖 国际组织化学和细胞化学联盟 2004年


专 利

1. Chinnaiyan AM, Han B, Kumar C. Recurrent Gene Fusions in Prostate Cancer. UM-10017/US-1/CIP. U.S.A. 2008


学术兼职

全国基础医学形态学实验室主任联席会副会长

吴阶平医学基金会病理学部常务委员

中国病理学工作者委员会常务委员

山东省医师协会病理科医师分会副主任委员

山东省病理学会青年委员会常务副主任委员

山东省疼痛医学会神经病理和分子病理委员会主任委员

山东省病理学会分子病理学组组长

医学实验室国家认可委员会评审员

中华医学会病理学分会泌尿及男性生殖组委员

来华留学生(医学) 教学专业委员会委员

山东省医师协会组织样本库及转化医学医师分会委员

山东大学学报医学版常务编委


发表论文 :  (#)为第一作者文章,(*)为通讯作者文章

1. Dong H, Hu J, Wang L, Qi M, Lu N, Tan X, Yang M, Bai X, Zhan X, Han B(*). SOX4 is activated by C-MYC in prostate cancer. Med Oncol. 2019 Sep 27;36(11):92. doi: 10.1007/s12032-019-1317-6.

2. Feng T, Zhao R, Sun F, Lu Q, Wang X, Hu J, Wang S, Gao L, Zhou Q, Xiong X, Dong X, Wang L, Han B(*). TXNDC9 regulates oxidative stress-induced androgen receptor signaling to promote prostate cancer progression. Oncogene. 2019 Sep 2. doi: 10.1038/s41388-019-0991-3. [Epub ahead of print]

3. Ji J, Xu R, Ding K, Bao G, Zhang X, Huang B, Wang X, Martinez A, Wang X, Li G, Miletic H, Thorsen F, Bjerkvig R, Xiang L, Han B, Chen A, Li XG, Wang J. Long noncoding RNA SChLAP1 forms a growth promoting complex with HNRNPL in human glioblastoma through stabilization of ACTN4 and activation of NF-κB signaling. Clin Cancer Res. 2019 Sep 6. pii: clincanres.0747.2019. doi: 10.1158/1078-0432.CCR-19-0747. [Epub ahead of print]

4. Hu J, Zhang J, Sun F, Qi M, Su P, Liu H, Gao L, Jiao M, Wu Z, Xiang L, Han B(*). Enhancer of zeste 2 polycomb repressive complex 2 subunit promotes sorafenib resistance of hepatocellular carcinoma though insulin-like growth factor 1 receptor. Anticancer Drugs. 2019 Aug;30(7):e0746.

5. Hu J, Sun F, Chen W, Zhang J, Zhang T, Qi M, Feng T, Liu H, Li X, Xing Y, Xiong X, Shi B, Zhou G,  Han B(*). BTF3 sustains cancer stem-like phenotype of prostate cancer via stabilization of BMI1. J Exp Clin Cancer Res. 2019 May 28;38(1):227.

6. Jiao M, Qi M, Zhang F, Hu J, Feng T, Zhao M, Li X, Liu H, Teng W, Zhang J, Liu Z, Zhang L, Wu Z,  Han B(*). CUL4B regulates cancer stem-like traits of prostate cancer cells by targeting BMI1 via miR200b/c. Prostate. 2019 Aug;79(11):1294-1303. (IF=3.566)

7. Liu T, Dong G, Xu F, Han B, Fang H, Huang Y, Zhou Y, Du L, Li M. Discovery of Turn-On Fluorescent Probes for Detecting Bcl-2 Protein. Anal Chem. 2019 May 7;91(9):5722-5728.

8. Wang X, Qi M, Zhang J, Sun X, Guo H, Pang Y, Zhang Q, Chen X, Zhang R, Liu Z, Liu L, Hao X, Han B(*). Differential response to neoadjuvant hormonal therapy in prostate cancer: Predictive morphological parameters and molecular markers. Prostate. 2019 May;79(7):709-719. (IF=3.566)

9. Qi M, Hu J, Cui Y, Jiao M, Feng T, Li X, Pang Y, Chen X, Qin R, Su P, Zhang H, Wang Y, Gong Y, Han B(*). CUL4B promotes prostate cancer progression by forming positive feedback loop with SOX4. Oncogenesis. 2019 14;8(3):23. (IF=4.722)

10. Zhao M, Qi M, Li X, Hu J, Zhang J, Jiao M, Bai X, Peng X, Han B(*). CUL4B/miR-33b/C-MYC axis promotes prostate cancer progression. Prostate. 2019 79(5):480-488. (IF=3.566)

11. Qi M, Jiao M, Li X, Hu J, Wang L, Zou Y, Zhao M, Zhang R, Liu H, Mi J, Zhang L, Liu L, Gong Y, Han B(*). CUL4B promotes gastric cancer invasion and metastasis-involvement of upregulation of HER2. Oncogene. 2018;37(8):1075-1085. (IF= 7.519)

12. Zhang L, Qi M, Feng T, Hu J, Wang L, Li X, Gao W, Liu H, Jiao M, Wu Z, Bai X, Bie Y, Liu L, Han B(*). IDH1R132H Promotes Malignant Transformation of Benign Prostatic Epithelium by Dysregulating MicroRNAs: Involvement of IGF1R-AKT/STAT3 Signaling Pathway. Neoplasia. 2018;20(2):207-217. (IF= 5.002)

13. Hu J, Su P, Jiao M, Bai X, Qi M, Liu H, Wu Z, Sun J, Zhou G, Han B(*). TRPS1 Suppresses Breast Cancer Epithelial-mesenchymal Transition Program as a Negative Regulator of SUZ12.Transl Oncol. 2018 Apr;11(2):416-425.

14. Chen X, Ding B, Zhang P, Geng S, Xu J, Han B(*). Intraductal carcinoma of the prostate: What we know and what we do not know. Pathol Res Pract. 2018 May;214(5):612-618.

15. Gu H, Sui S, Cui X, Han B, Zhang C, Qi M, Li C, Liu Z(*). Thyroid carcinoma producing β-human chorionic gonadotropin shows different clinical behavior. Pathol Int. 2018 Apr;68(4):207-213.

16. Zhang Y, Wang LN, Lin YN, Xing YX, Shi Y, Zhao J, Chen WW(*), Han B. The novel long noncoding RNA LOC283070 is involved in the transition of LNCaP cells into androgen-independent cells via its interaction with PHB2. Asian J Androl. 2018 Sep-Oct;20(5):511-517.

17. Wang L, Song G, Zhang X, Feng T ,Pan J,Chen W,Yang M, Bai X, Pang Y, Yu J,Han J,Han B(*). PADI2-mediated citrullination promotes prostate cancer progression. Cancer Research, 2017;77(21):5755-5768. (IF=9.329)

18. Li P, Zhang 2, Yang M, Qi M, Jin X, Han B(*)..Cul4B is a novel prognostic marker in cholangiocarcinoma.Oncol Lett. 2017;14(2):1265-1274.(IF=1.459)

19. Fu W, Tao T, Qi M, Wang L, Hu J, Li X, Xing N, Du R, Han B(*).MicroRNA-132/212 Upregulation Inhibits TGF-β-Mediated Epithelial-Mesenchymal Transition of Prostate Cancer Cells by Targeting SOX4. Prostate. 2016;76(16):1560-1570. (IF=3.566)

20. Ma Z, Lin Y, Cheng Y, Wu W, Cai R, Chen S, Shi B, Han B, Shi X, Zhou Y, Du L, Li M. Discovery of the First Environment-Sensitive Near-Infrared (NIR) Fluorogenic Ligand for α1-Adrenergic Receptors Imaging in Vivo. J Med Chem. 2016; 59(5):2151-62. (IF= 5.447)

21. Li C, Dong H, Fu W, Qi M, Han B(*).Thyroid-like Follicular Carcinoma of the Kidney and Papillary Renal Cell Carcinoma with Thyroid-like Feature: Comparison of Two Cases and Literature Review. Ann Clin Lab Sci. 2015; 45(6):707-12. (IF= 0.910)

22. Wang J, Yang M, Li Y, Han B(*).The Role of MicroRNAs in the Chemoresistance of Breast Cancer. Drug Dev Res. 2015; 76(7):368-74. (IF= 0.767)

23. Wang L, Song G, Tan W, Qi M, Zhang L, Chan J, Yu J, Han J, Han B(*). miR-573 inhibits prostate cancer metastasis by regulating epithelial-mesenchymal transition. Oncotarget. 2015; 6(34):35978-90. (IF= 6.359)

24. Yang M, Wang J, Wang L, Shen C, Su B, Qi M, Hu J, Gao W, Tan W, Han B(*).Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells. Prostate. 2015;75(13):1363-75. (IF=3.566)

25. Tan W, Wang L, Ma Q, Qi M, Lu N, Zhang L, Han B(*). Adiponectin as a potential tumor suppressor inhibiting epithelial-to-mesenchymal transition but frequentlysilenced in prostate cancer by promoter methylation. Prostate. 2015; 75(11):1197-205.(IF=3.566)

26. Qi M, Liu Z, Shen C, Wang L, Zeng J, Wang C, Li C, Fu W, Sun Y, Han B(*). Overexpression of ETV4 is associated with poor prognosis in prostate cancer: involvement of uPA/uPAR and MMPs. Tumour Biol. 2015; 36(5):3565-72. (IF=2.840)

27. Lu N, Lin T, Wang L, Qi M, Liu Z, Dong H, Zhang X, Zhai C, Wang Y, Liu L, Xiang L, Qi L, Han B(*), Li J(*). Association of SOX4 regulated by tumor suppressor miR-30a with     poor prognosis in low-grade chondrosarcoma. Tumour Biol. 2015; 36(5):3843-52. (IF=2.840)

28. Yuan J, Han B, Hu H, Qian Y, Liu Z, Wei Z, Liang X, Jiang B, Shao C, Gong Y(*). CUL4B activates Wnt/β-catenin signalling in hepatocellular carcinoma by repressing Wnt antagonists. J Pathol. 2015; 235(5):784-95. (IF=7.330)

29. Xu YF , Ge FJ , Han B(#) , Yang XQ , Su H , Zhao AC , Zhao MH , Yang YB , Yang J(*). High-mobility group box 1 expression and lymph node metastasis in intrahepatic cholangiocarcinoma. World J Gastroenterol. 2015; 21(11):3256-65. (IF=2.433)

30. Xiang YJ, Guo MM, Zhou CJ, Liu L, Han B, Kong LY, Gao ZC, Ma ZB, Wang L, Feng M, Chen HY, Jia GT, Gao DZ, Zhang Q, Li L, Li YY, Yu ZG. Absence of gamma- interferon -inducible lysosomal thiol reductase (GILT) is associated with poor disease-free survival in breast cancer patients. PLoS One. 2014; 9(10):e109449.(IF=3.534)

31. Wang L, Song G, Chang X, Tan W, Pan J, Zhu X, Liu Z, Qi M, Yu J, Han B(*). The role of TXNDC5 in castration resistant prostate cancer – involvement of androgen receptor signaling pathway. Oncogene. 2015; 34(36):4735-45. (IF=8.559)

32. Zhang J, Shen C, Wang L, Ma Q, Xia P, Qi M, Yang M, Han B(*).Metformin inhibits   epithelial-mesenchymal transition in prostate cancer cells: involvement of the tumor suppressor miR30a and its target gene SOX4. Biochem Biophys Res Commun. 2014; 452(3):746-52. (IF=2.281)

33. Wang W , Zhang J , Zhan X , Lin T , Yang M , Hu J , Han B(*) , Hu S(*) .  SOX4 is      associated   with poor prognosis in cholangiocarcinoma. Biochem Biophys Res Commun.  2014; 452(3):614-21. (IF=2.281)

34. Yang X, Wang W, Wang C, Wang L, Yang M, Qi M, Su H, Sun X, Liu Z, Zhang J, Qin X, Han B.(*). Characterization of EGFR family gene aberrations in cholangiocarcinoma. Oncol Rep. 2014; 32(2):700-8. (IF=2.191)

35. Qi M, Yang XQ, Lin T, Li Y, Yuan HQ, Ren YB, Sun XB, Zhang J, Qin XM, Han B(*). ERG Rearrangement is Associated with Prostate Cancer-Related Death in Chinese Prostate Cancer Patients. Plos One. PLoS One.2014; 9(2):e84959. (IF=3.73)

36. Wang L, Li YJ, Zhang F, Yan HQ, Li XZ, Yang XQ, Qi M, Chang W.Y. Y, Fu WW, Zhang J, Han B(*). ERG Cooperatives with SOX4 to Promote Epithelial–mesenchymal transition in Prostate Cancer. The Prostate. 2014; 74(6):647-58. (IF=3.843)

37. Wang C, Wang L, Su B, Lu N, Song J, Yang X, Fu W, Tan W, Han B(*). Serine protease inhibitor Kazal type1 promotes epithelial-mesenchymal transition through EGFR signaling pathway in prostate cancer. Prostate. 2014; 74(7):689-701. (IF=3.566)

38. Wang L, Li YJ, Yang XQ, Chang W.Y. Y, Qi M, Zhou ZQ, Zhang J, Han B(*). SOX4 is Associated with Poor Prognosis in Prostate Cancer and Promotes Epithelial- mesenchymal Transition in vitro Prostate Cancer and P D. Prostate Cancer Prostatic Dis. 2013 ; 16(4):301-7. (IF=2.811)

39. Wang J, Wang L, Song G, Han B(*). The mechanism through which octreotide inhibits hepatic stellate cell activity. Mol Med Rep. 2013; 7(5):1559-64. (IF=0.418)

40. Xiang L, Zhou G, Su P, Xia S, Han B, Wang Y, Zhang T. Could postmortem hemorrhage occur in the brain?: a preliminary study on the establishment and investigation of postmortem hypostatic hemorrhage using rabbit models. Am J Forensic Med Pathol. 2013; 34 (2):147-9. (IF=0.701)

41. Ma W, Zhuang L, Han B (*), Tang B. Association between glutathione S-transferase T1 null genotype and gastric cancer risk: a meta-analysis of 48 studies. PLoS One. 2013; 8(4):e60833.  (IF=3.73)

42. Qi M, Li Y, Liu J, Yang X, Wang L, Zhou Z, Han B(*). Morphologic features of carcinomas with recurrent gene fusions. Adv Anat Pathol. 2012; 19(6):417-24. (IF=3.412)

43. Hu Z, Gu Y, Han B, Zhang J, Li Z, Tian K, Young CY, Yuan H. Knockdown of AGR2 induces cellular senescence in prostate cancer cells. Carcinogenesis. 2012; 33(6):1178-86 (IF=5.635)

44. Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, Williamsen S,                 Hodge P, Meinke J, Blasé A, Penabella Y, Day JR, Varambally R, Han B, Wood D, Wang L, Sanda MG, Rubin MA, Rhodes DR, Hollenbeck B, Sakamoto K, Silberstein JL, Fradet Y, Amberson JB, Meyers S, Palanisamy N, Rittenhouse H, Wei JT, Groskopf J, Chinnaiyan AM. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med. 3(94): 94ra72. 2011. (IF=10.757)

45. Mehra R, Kumar-Sinha C, Shankar S, Lonigro RJ, Jing X, Philips NE, Siddiqui J, Han B, Cao X, Smith DC, Shah RB, Chinnaiyan AM, Pienta KJ. Characterization of bone metastases from rapid autopsies of prostate cancer patients. Clin Cancer Res. 2011; 17(12): 3924-32. (IF=7.837)

46. Zhang C, Li H, Wang Y, Liu W, Zhang Q, Zhang T, Zhang X, Han B, Zhou G. Epigenetic inactivation of the tumor suppressor gene RIZ1 in hepatocellular carcinoma involves both DNA methylation and histone modifications. J Hepatol. 2010; 53(5):889-95. (IF=9.858)

47. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghoshd D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM. Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol. 2010; 58:12-8. (IF=10.476)

48. Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K, Shankar S, Han B, Cao Q, Cao X, Suleman K, Kumar-Sinha C, Dhanasekaran SM, Chen YB, Esgueva R, Banerjee S, LaFargue CJ, Siddiqui J, Demichelis F, Moeller P, Bismar TA, Kuefer R, Fullen DR, Johnson TM, Greenson JK, Giordano TJ, Tan P, Tomlins SA, Varambally S, Rubin MA, Maher CA, Chinnaiyan AM. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med. 2010; 16(7):793-8. (IF=22.864)

49. Han B(#), Suleman K, Wang L, Siddiqui J, Sercia L, Magi-Galluzzi C, Palanisamy N, Chinnaiyan AM, Zhou M, Shah RB. ETS gene aberrations in atypical cribriform lesions of the prostate: Implications for the distinction between intraductal carcinoma of the prostate and cribriform high-grade prostatic intraepithelial neoplasia. Am J Surg Pathol. 2010; 34(4):478-85. (IF=4.868)

50. Shah RB, Magi-Galluzzi C, Han B, Zhou M. Atypical cribriform lesions of the prostate: relationship to prostatic carcinoma and implication for diagnosis in prostate biopsies. Am J Surg Pathol. 2010; 34(4):470-7. (IF=4.868)

51. Wang XS, Prensner JR, Chen G, Cao Q, Han B, Dhanasekaran SM, Ponnala R, Cao X, Varambally S, Thomas DG, Giordano TJ, Beer DG, Palanisamy N, Sartor MA, Omenn GS, Chinnaiyan AM. An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. Nat Biotechnol. 2009; 27(11):1005-11. (IF=32.438)

52. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, Wu T, Regan MM, Meyer CA, Carroll JS, Manrai AK, J?nne OA, Balk SP, Mehra R, Han B, Chinnaiyan AM, Rubin MA, True L, Fiorentino M, Fiore C, Loda M, Kantoff PW, Liu XS, Brown M. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 2009; 138(2):245-56. (IF=31.957)

53. Han B(#), Mehra R, Suleman K, Tomlins SA, Wang L, Singhal N, Linetzky KA, Palanisamy N, Zhou M, Chinnaiyan AM, Shah RB. Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Mod Pathol. 2009; 22(9):1176-85. (IF=5.253)

54. Han B(#), Mehra R, Lonigro RJ, Wang L, Suleman K, Menon A, Palanisamy N, Tomlins SA, Chinnaiyan AM, Shah RB. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol. 2009; 22(8):1083-93. (IF=5.253)

55. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009; 457(7231):910-4. (IF=38.597)

56. Transcriptome sequencing to detect gene fusions in cancer. Maher CA, Kumar-Sinha C, Cao X, Kalyana-Sundaram S, Han B, Jing X, Sam L, Barrette T, Palanisamy N, Chinnaiyan AM(*). Nature. 2009; 458(7234):97-101. (IF=38.597)

57. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kumar-Sinha C, Lonigro RJ, Palanisamy N, Maher CA, Chinnaiyan AM. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science. 2008; 322(5908):1695-9. (IF=31.027)

58. Han B(#), Mehra R, Dhanasekaran SM, Yu J, Menon A, Lonigro RJ, Wang X, Gong Y, Wang L, Shankar S, Laxman B, Shah RB, Varambally S, Palanisamy N, Tomlins SA, Kumar-Sinha C, Chinnaiyan AM(*). A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res. 2008; 68(18):7629-37. (IF=8.65)

59. Mehra R, Han B, Tomlins SA, Wang L, Menon A, Wasco MJ, Shen R, Montie JE, Chinnaiyan AM, Shah RB. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res. 2007; 67(17):7991-5. (IF=8.65)

60. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, Yu J, Wang L, Montie JE, Rubin MA, Pienta KJ, Roulston D, Shah RB, Varambally S, Mehra R, Chinnaiyan AM. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature. 2007; 448(7153):595-9. (IF=38.597)

61. Nakamura M, Han B, Nishishita T, Bai Y, Kakudo K. Calcitonin targets extracellular signal-regulated kinase signaling pathway in human cancers. J Mol Endocrinol. 2007; 39(6):375-84. (IF=3.577)

62. Nakamura M, Han B, Nunobiki O, Kakudo K. Adrenomedullin: a tumor progression factor via angiogenic control.Curr Cancer Drug Targets. 2006; 6(7):635-43. (IF=4)

63. Mori I, Han B, Wang X, Taniguchi E, Nakamura M, Nakamura Y, Bai Y, Kakudo K. Mastopathic fibroadenoma of the breast: a pitfall of aspiration cytology. Cytopathology. 2006;17(5):233-8. (IF=1.714)

64. Ishii A, Nakamura M, Nakamura A, Takeda K, Han B, Kakudo K. Expression of calcitonin receptor in rat mammary gland during lactation. Endocr J. 2006; 53(3):317-24. (IF=2.228)

65. Han B(#), Mori I, Nakamura M, Wang X, Ozaki T, Nakamura Y, Kakudo K. Myoepithelial carcinoma arising in an adenomyoepithelioma of the breast: case report with immunohistochemical and mutational analysis. Pathol Int. 2006; 56(4):211-6. (IF=1.722)

66. Han B(#), Nakamura M, Zhou G, Ishii A, Nakamura A, Bai Y, Mori I, Kakudo K. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor. Int J Oncol. 2006; 28(4):807-14. (IF=2.657)

67. Han B(#), Mori I, Wang X, Nakamura M, Nakamura Y, Kakudo K. Combined small-cell carcinoma of the stomach: p53 and K-ras gene mutational analysis supports a monoclonal origin of three histological components. Int J Exp Pathol. 2005; 86(4):213-8. (IF=2.04)

68. Han B(#), Nakamura M, Mori I, Nakamura Y, Kakudo K. Urokinase-type plasminogen activator system and breast cancer (Review). Oncol Rep. 2005; 14(1):105-12. (IF=2.297)

69. Han B(#), Zhou G, Zhang Q, Zhang J, Wang X, Tang W, Kakudo K. Effect of arsenic trioxide (ATO) on human lung carcinoma PG cell line: ATO induced apoptosis of PG cells and decreased expression of Bcl-2, Pgp. J Exp Ther Oncol. 2004; 4(4):335-42.




更多图片